Bioatla
Price & Volume
Stats
See more52W Range | $0.24-$1.74 |
Market Cap | $51.1M |
Shares Short | 4M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 31.6% |
Gross Profit (12 Mos) | -$46.7M |
Diluted EPS | -$1.15 |
News
See moreYahoo Finance • 3 days ago
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
Yahoo Finance • 10 days ago
Applied Therapeutics, Omeros, And Others Post Sharp Moves After Market Close
Yahoo Finance • 16 days ago
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
Yahoo Finance • 2 months ago
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
About
CEO | Dr. Jay M. Short Ph.D. |
CFO | Mr. Richard A. Waldron |
Address | 11085 Torreyana Road, San Diego, CA, United States, 92121 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 61 |
